Bayer’s riociguat Phase III trial data on pulmonary hypertension to be presented at ACCP meeting

Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American College of Chest Physicians (ACCP) annual meeting October 20 – 25, in Atlanta, GA.  Data from two pivotal, Phase III trials researching riociguat in patients with for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) will be presented as late-breaking abstracts in oral presentation sessions.

"At Bayer, we are dedicated to researching new treatment options for people living with devastating diseases, like pulmonary hypertension," said Pamela A. Cyrus , M.D., Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals.  "We are pleased to present top-line results of riociguat and its potential as a treatment option for PAH and CTEPH."

The studies to be presented are:

• Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double-blind, placebo-controlled study (CHEST-1)
  • Abstract 1462924; Late Breaking Abstract Session
  • October 23, 2012, 4:30 p.m. – 5:45 p.m., Convention Center,
    Room C206

• Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study (PATENT-1)
  • Abstract 1462799 Late Breaking Abstract Session
  • October 23, 2012, 4:30 p.m. – 5:45 p.m., Convention Center,
    Room C206